Tezepelumab, the "upstream" biologic that blocks TSLP to interrupt allergic and inflammatory pathways early, is gaining traction for severe asthma.
Researchers analyzed data from the Danish Severe Asthma Register on 270 patients started on tezepelumab. Notably, nearly two-thirds (63%) were switching from other biologics - suggesting clinicians turned to tezepelumab when previous options fall short.
After 12 months, the results were impressive across both groups:
- Exacerbations dropped by 69%.
- Maintenance oral corticosteroid use decreased significantly.
- Asthma symptoms improved
The majority achieved a clinical response - rates on par with other biologics in Denmark.
Even more encouraging: biologic-naïve patients were more than twice as likely to reach full clinical remission (35% vs. 15% in switchers).
These real-world findings reinforce tezepelumab's potential as a versatile option in severe asthma, effective in complex cases with mixed or low type 2 inflammation and a good choice for patients needing to switch therapies.
References:
https://www.jaci-inpractice.org/article/S2213-2198(25)00849-9/fulltext